1
|
Miller L, Impelmann A, Bauer F, Breit B. Carbonylation as a Key Step in New Tandem Reactions - A Route to BODIPYs. Chemistry 2023:e202303752. [PMID: 38109037 DOI: 10.1002/chem.202303752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2023] [Revised: 12/15/2023] [Accepted: 12/18/2023] [Indexed: 12/19/2023]
Abstract
Herein, a highly efficient five-step reaction sequence to BODIPYs is presented. The key step is the combination of transition metal-catalyzed in-situ generation of aldehydes and their subsequent organocatalytic activation to yield dipyrromethanes, which are further converted to the corresponding BODIPY. Classic syntheses towards BODIPYs have relied on aldehydes or acid chlorides, which are often not commercially available and rather sensitive to handle. The presented approach starts from readily available and stable alkenes or aryl-bromides, which allows to extend the range of readily available BODIPYs that can be tailored for their specific use. The synthesis of 55 derivatives with overall yields of up to 78 % demonstrates the wide applicability and advantages of the presented method.
Collapse
Affiliation(s)
- Lukas Miller
- Institut für Organische Chemie, Albert-Ludwigs-Universität Freiburg, Albertstraße 21, 79104, Freiburg im Breisgau, Germany
| | - Alba Impelmann
- Institut für Organische Chemie, Albert-Ludwigs-Universität Freiburg, Albertstraße 21, 79104, Freiburg im Breisgau, Germany
| | - Felix Bauer
- Institut für Organische Chemie, Albert-Ludwigs-Universität Freiburg, Albertstraße 21, 79104, Freiburg im Breisgau, Germany
| | - Bernhard Breit
- Institut für Organische Chemie, Albert-Ludwigs-Universität Freiburg, Albertstraße 21, 79104, Freiburg im Breisgau, Germany
| |
Collapse
|
2
|
Wessig P, Krebs S. N‐Aroylsulfonamide‐Photofragmentation (ASAP)‐A Versatile Route to Biaryls. European J Org Chem 2021. [DOI: 10.1002/ejoc.202100955] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Pablo Wessig
- Institut für Chemie Universität Potsdam Karl-Liebknecht-Str. 24–25 14476 Potsdam Germany
| | - Saskia Krebs
- Institut für Chemie Universität Potsdam Karl-Liebknecht-Str. 24–25 14476 Potsdam Germany
| |
Collapse
|
3
|
Verma S, Ravichandiran V, Ranjan N, Flora SJS. Recent Advances in Therapeutic Applications of Bisbenzimidazoles. Med Chem 2021; 16:454-486. [PMID: 31038072 DOI: 10.2174/1573406415666190416120801] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2018] [Revised: 03/19/2019] [Accepted: 04/08/2019] [Indexed: 12/16/2022]
Abstract
Nitrogen-containing heterocycles are one of the most common structural motifs in approximately 80% of the marketed drugs. Of these, benzimidazoles analogues are known to elicit a wide spectrum of pharmaceutical activities such as anticancer, antibacterial, antiparasitic, antiviral, antifungal as well as chemosensor effect. Based on the benzimidazole core fused heterocyclic compounds, crescent-shaped bisbenzimidazoles were developed which provided an early breakthrough in the sequence-specific DNA recognition. Over the years, a number of functional variations in the bisbenzimidazole core have led to the emergence of their unique properties and established them as versatile ligands against several classes of pathogens. The present review provides an overview of diverse pharmacological activities of the bisbenzimidazole analogues in the past decade with a brief account of its development through the years.
Collapse
Affiliation(s)
- Smita Verma
- National Institute of Pharmaceutical Education and Research, ITI Compound, Raebareli, 229010, India.,National Institute of Pharmaceutical Education and Research, Kolkata, Maniktala Main Road, Kolkata, 700054, India
| | - Vishnuvardh Ravichandiran
- National Institute of Pharmaceutical Education and Research, Kolkata, Maniktala Main Road, Kolkata, 700054, India
| | - Nihar Ranjan
- National Institute of Pharmaceutical Education and Research, ITI Compound, Raebareli, 229010, India
| | - Swaran J S Flora
- National Institute of Pharmaceutical Education and Research, ITI Compound, Raebareli, 229010, India
| |
Collapse
|
4
|
Hu XG, Li X, Yang SI. Novel photochromic infinite coordination polymer particles derived from a diarylethene photoswitch. Chem Commun (Camb) 2015; 51:10636-9. [PMID: 26041619 DOI: 10.1039/c5cc02447a] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
A novel infinite coordination polymer (DAE-ICP) based on zinc nitrite and a diarylethene photoswitch, with reversible photochromic properties in solution and the solid state upon applying photostimuli, was synthesized and characterized by FT-IR, EDX, FE-SEM and FE-TEM.
Collapse
Affiliation(s)
- Xiao Guang Hu
- Department of Applied Chemistry, Kyung Hee University, Yongin-Si 446-701, Republic of Korea.
| | | | | |
Collapse
|
5
|
Roopashree R, Mohan CD, Swaroop TR, Jagadish S, Raghava B, Balaji KS, Jayarama S, Basappa, Rangappa KS. Novel synthetic bisbenzimidazole that targets angiogenesis in Ehrlich ascites carcinoma bearing mice. Bioorg Med Chem Lett 2015; 25:2589-93. [DOI: 10.1016/j.bmcl.2015.04.010] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2015] [Revised: 03/16/2015] [Accepted: 04/01/2015] [Indexed: 01/03/2023]
|
6
|
Lamotte Y, Faucher N, Sançon J, Pineau O, Sautet S, Fouchet MH, Beneton V, Tousaint JJ, Saintillan Y, Ancellin N, Nicodeme E, Grillot D, Martres P. Discovery of novel indazole derivatives as dual angiotensin II antagonists and partial PPARγ agonists. Bioorg Med Chem Lett 2014; 24:1098-103. [PMID: 24462665 DOI: 10.1016/j.bmcl.2014.01.004] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2013] [Revised: 01/02/2014] [Accepted: 01/05/2014] [Indexed: 11/20/2022]
Abstract
Identification of indazole derivatives acting as dual angiotensin II type 1 (AT1) receptor antagonists and partial peroxisome proliferator-activated receptor-γ (PPARγ) agonists is described. Starting from Telmisartan, we previously described that indole derivatives were very potent partial PPARγ agonists with loss of AT1 receptor antagonist activity. Design, synthesis and evaluation of new central scaffolds led us to the discovery of pyrrazolopyridine then indazole derivatives provided novel series possessing the desired dual activity. Among the new compounds, 38 was identified as a potent AT1 receptor antagonist (IC50=0.006 μM) and partial PPARγ agonist (EC50=0.25 μM, 40% max) with good oral bioavailability in rat. The dual pharmacology of compound 38 was demonstrated in two preclinical models of hypertension (SHR) and insulin resistance (Zucker fa/fa rat).
Collapse
Affiliation(s)
- Yann Lamotte
- Centre de Recherches François Hyafil, GlaxoSmithKline R&D, 25 avenue du Québec, 91140 Villebon-sur-Yvette, France.
| | - Nicolas Faucher
- Centre de Recherches François Hyafil, GlaxoSmithKline R&D, 25 avenue du Québec, 91140 Villebon-sur-Yvette, France
| | - Julien Sançon
- Centre de Recherches François Hyafil, GlaxoSmithKline R&D, 25 avenue du Québec, 91140 Villebon-sur-Yvette, France
| | - Olivier Pineau
- Centre de Recherches François Hyafil, GlaxoSmithKline R&D, 25 avenue du Québec, 91140 Villebon-sur-Yvette, France
| | - Stéphane Sautet
- Centre de Recherches François Hyafil, GlaxoSmithKline R&D, 25 avenue du Québec, 91140 Villebon-sur-Yvette, France
| | - Marie-Hélène Fouchet
- Centre de Recherches François Hyafil, GlaxoSmithKline R&D, 25 avenue du Québec, 91140 Villebon-sur-Yvette, France
| | - Véronique Beneton
- Centre de Recherches François Hyafil, GlaxoSmithKline R&D, 25 avenue du Québec, 91140 Villebon-sur-Yvette, France
| | - Jean-Jacques Tousaint
- Centre de Recherches François Hyafil, GlaxoSmithKline R&D, 25 avenue du Québec, 91140 Villebon-sur-Yvette, France
| | - Yannick Saintillan
- Centre de Recherches François Hyafil, GlaxoSmithKline R&D, 25 avenue du Québec, 91140 Villebon-sur-Yvette, France
| | - Nicolas Ancellin
- Centre de Recherches François Hyafil, GlaxoSmithKline R&D, 25 avenue du Québec, 91140 Villebon-sur-Yvette, France
| | - Edwige Nicodeme
- Centre de Recherches François Hyafil, GlaxoSmithKline R&D, 25 avenue du Québec, 91140 Villebon-sur-Yvette, France
| | - Didier Grillot
- Centre de Recherches François Hyafil, GlaxoSmithKline R&D, 25 avenue du Québec, 91140 Villebon-sur-Yvette, France
| | - Paul Martres
- Centre de Recherches François Hyafil, GlaxoSmithKline R&D, 25 avenue du Québec, 91140 Villebon-sur-Yvette, France
| |
Collapse
|
7
|
Ros A, Estepa B, Bermejo A, Álvarez E, Fernández R, Lassaletta JM. Phosphino Hydrazones as Suitable Ligands in the Asymmetric Suzuki–Miyaura Cross-Coupling. J Org Chem 2012; 77:4740-50. [DOI: 10.1021/jo300548z] [Citation(s) in RCA: 79] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Abel Ros
- Instituto de Investigaciones Químicas (IIQ), CSIC/US, Américo Vespucio
49, 41092 Seville, Spain
| | - Beatriz Estepa
- Departamento de Química Orgánica, Universidad de Sevilla, Apdo. de Correos No. 1203, 41071, Seville,
Spain
| | - Antonio Bermejo
- Departamento de Química Orgánica, Universidad de Sevilla, Apdo. de Correos No. 1203, 41071, Seville,
Spain
| | - Eleuterio Álvarez
- Instituto de Investigaciones Químicas (IIQ), CSIC/US, Américo Vespucio
49, 41092 Seville, Spain
| | - Rosario Fernández
- Departamento de Química Orgánica, Universidad de Sevilla, Apdo. de Correos No. 1203, 41071, Seville,
Spain
| | - José M. Lassaletta
- Instituto de Investigaciones Químicas (IIQ), CSIC/US, Américo Vespucio
49, 41092 Seville, Spain
| |
Collapse
|
8
|
Structural basis for telmisartan-mediated partial activation of PPAR gamma. Hypertens Res 2012; 35:715-9. [DOI: 10.1038/hr.2012.17] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
9
|
Casimiro-Garcia A, Filzen GF, Flynn D, Bigge CF, Chen J, Davis JA, Dudley DA, Edmunds JJ, Esmaeil N, Geyer A, Heemstra RJ, Jalaie M, Ohren JF, Ostroski R, Ellis T, Schaum RP, Stoner C. Discovery of a Series of Imidazo[4,5-b]pyridines with Dual Activity at Angiotensin II Type 1 Receptor and Peroxisome Proliferator-Activated Receptor-γ. J Med Chem 2011; 54:4219-33. [DOI: 10.1021/jm200409s] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Agustin Casimiro-Garcia
- Pfizer Global Research and Development, Groton Laboratories, Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Gary F. Filzen
- Pfizer Global Research and Development, Groton Laboratories, Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Declan Flynn
- Pfizer Global Research and Development, Groton Laboratories, Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Christopher F. Bigge
- Pfizer Global Research and Development, Groton Laboratories, Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Jing Chen
- Pfizer Global Research and Development, Groton Laboratories, Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Jo Ann Davis
- Pfizer Global Research and Development, Groton Laboratories, Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Danette A. Dudley
- Pfizer Global Research and Development, Groton Laboratories, Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Jeremy J. Edmunds
- Pfizer Global Research and Development, Groton Laboratories, Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Nadia Esmaeil
- Pfizer Global Research and Development, Groton Laboratories, Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Andrew Geyer
- Pfizer Global Research and Development, Groton Laboratories, Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Ronald J. Heemstra
- Pfizer Global Research and Development, Groton Laboratories, Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Mehran Jalaie
- Pfizer Global Research and Development, Groton Laboratories, Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Jeffrey F. Ohren
- Pfizer Global Research and Development, Groton Laboratories, Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Robert Ostroski
- Pfizer Global Research and Development, Groton Laboratories, Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Teresa Ellis
- Pfizer Global Research and Development, Groton Laboratories, Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Robert P. Schaum
- Pfizer Global Research and Development, Groton Laboratories, Eastern Point Rd, Groton, Connecticut 06340, United States
| | - Chad Stoner
- Pfizer Global Research and Development, Groton Laboratories, Eastern Point Rd, Groton, Connecticut 06340, United States
| |
Collapse
|
10
|
Characterization of new PPARgamma agonists: benzimidazole derivatives-importance of positions 5 and 6, and computational studies on the binding mode. Bioorg Med Chem 2010; 18:5885-95. [PMID: 20656494 DOI: 10.1016/j.bmc.2010.06.102] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2009] [Revised: 06/28/2010] [Accepted: 06/29/2010] [Indexed: 11/23/2022]
Abstract
In this and previous studies we investigated the importance of partial structures of Telmisartan on PPARgamma activation. The biphenyl-4-ylmethyl moiety at N1 and residues at C2 of the central benzimidazole were identified to be essential for receptor activation and potency of receptor binding. Now we focused our attention on positions 5 and 6 of the central benzimidazole and introduced bromine (3b-5/6, 3c), phenylcarbonyl (3d-5/6), hydroxy(phenyl)methyl (3g-5/6), hydroxymethyl (3h-5/6) and formyl (3i) groups. The selection of these moieties was inspired by the structure of Losartan and its metabolite EXP3179. In order to increase the hydrophobicity of the central part of the molecule, the benzimidazole was exchanged by a naphtho[2,3-d]imidazole (5). The compounds 3a-3i and 5 were tested in a differentiation assay using 3T3-L1 preadipocytes and a luciferase assay using COS-7 cells, transiently transfected with pGal4-hPPARgammaDEF, pGal5-TK-pGL3 and pRL-CMV, as established models for the assessment of cellular PPARgamma activation. An enhanced effect on PPARgamma activation could be observed if lipophilic moieties are introduced in these positions. 4'-[(2-Propyl-1H-naphtho[2,3-d]imidazol-1-yl)methyl]biphenyl-2-carboxylic acid (5) was identified as the most potent compound with an EC(50) of 0.26muM and the profile of a full agonist. Together with compounds of the former structure-activity relationship study (position 2-substituted benzimidazole derivatives 4a-4j), the binding mode of Telmisartan and its derivatives have been analyzed in 3D pharmacophore-driven docking experiments.
Collapse
|
11
|
Mizuno CS, Chittiboyina AG, Shah FH, Patny A, Kurtz TW, Pershadsingh HA, Speth RC, Karamyan VT, Carvalho PB, Avery MA. Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome. J Med Chem 2010; 53:1076-85. [PMID: 20073471 DOI: 10.1021/jm901272d] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
In addition to lowering blood pressure, telmisartan, an angiotensin (AT(1)) receptor blocker, has recently been shown to exert pleiotropic effects as a partial agonist of nuclear peroxisome proliferator-activated receptor gamma (PPAR gamma). On the basis of these findings and docking pose similarity between telmisartan and rosiglitazone in PPAR gamma active site, two classes of benzimidazole derivatives were designed and synthesized as dual PPAR gamma agonist/angiotensin II antagonists for the possible treatment of metabolic syndrome. Compound 4, a bisbenzimidazole derivative showed the best affinity for the AT(1) receptor with a K(i) = 13.4 nM, but it was devoid of PPAR gamma activity. On the other hand 9, a monobenzimidazole derivative, showed the highest activity in PPAR gamma transactivation assay (69% activation) with no affinity for the AT(1) receptor. Docking studies lead to the designing of a molecule with dual activity, 10, with moderate PPARgamma activity (29%) and affinity for the AT(1) receptor (K(i) = 2.5 microM).
Collapse
Affiliation(s)
- Cassia S Mizuno
- Department of Medicinal Chemistry, School of Pharmacy, The University of Mississippi, University, Mississippi 38677, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|